Consequently, AAV9-Slc25a21 administration also increased the levels of acetyl-CoA in AKI kidneys compared to AKI controls, together with crotonyl-CoA, another intermediary metabolite derived from the conversion of 2-oxoadipate into acetyl-CoA (Fig. 5I). The gene discussed is SLC25A21; the disease is acute kidney injury.